These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 23686569)

  • 1. Performance of anti-cyclic citrullinated Peptide assays differs in subjects at increased risk of rheumatoid arthritis and subjects with established disease.
    Demoruelle MK; Parish MC; Derber LA; Kolfenbach JR; Hughes-Austin JM; Weisman MH; Gilliland W; Edison JD; Buckner JH; Mikuls TR; O'Dell JR; Keating RM; Gregersen PK; Norris JM; Holers VM; Deane KD
    Arthritis Rheum; 2013 Sep; 65(9):2243-52. PubMed ID: 23686569
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A comparative study of IgG second- and third-generation anti-cyclic citrullinated peptide (CCP) ELISAs and their combination with IgA third-generation CCP ELISA for the diagnosis of rheumatoid arthritis.
    dos Anjos LM; Pereira IA; d 'Orsi E; Seaman AP; Burlingame RW; Morato EF
    Clin Rheumatol; 2009 Feb; 28(2):153-8. PubMed ID: 18795390
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-citrullinated protein antibodies in the diagnosis of rheumatoid arthritis (RA): diagnostic performance of automated anti-CCP-2 and anti-CCP-3 antibodies assays.
    Vos I; Van Mol C; Trouw LA; Mahler M; Bakker JA; Van Offel J; De Clerck L; Huizinga TW
    Clin Rheumatol; 2017 Jul; 36(7):1487-1492. PubMed ID: 28578492
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-cyclic citrullinated peptide antibodies: a comparison of different assays for the diagnosis of rheumatoid arthritis.
    Debaugnies F; Servais G; Badot V; Noubouossie D; Willems D; Corazza F
    Scand J Rheumatol; 2013; 42(2):108-14. PubMed ID: 23126558
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of Serological Biomarkers in Rheumatoid Arthritis and Their Combination to Improve Diagnostic Performance.
    Martinez-Prat L; Nissen MJ; Lamacchia C; Bentow C; Cesana L; Roux-Lombard P; Gabay C; Mahler M
    Front Immunol; 2018; 9():1113. PubMed ID: 29928272
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A comparison of the frequency of antibodies to cyclic citrullinated peptides using a third generation anti-CCP assay (CCP3) in systemic sclerosis, primary biliary cirrhosis and rheumatoid arthritis.
    Santiago M; Baron M; Miyachi K; Fritzler MJ; Abu-Hakima M; Leclercq S; Bell M; Hudson M; Mathieu JP; Taillefer S; Jones N; Docherty P; Khraishi M; Markland J; Pope J; Robinson D; Smith D; Sutton E
    Clin Rheumatol; 2008 Jan; 27(1):77-83. PubMed ID: 17570008
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Third generation anti-citrullinated peptide antibody assay is a sensitive marker in rheumatoid factor negative rheumatoid arthritis.
    Swart A; Burlingame RW; Gürtler I; Mahler M
    Clin Chim Acta; 2012 Dec; 414():266-72. PubMed ID: 23022338
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative performance analysis of 4 different anti-citrullinated protein assays in the diagnosis of rheumatoid arthritis.
    Mutlu N; Bicakcigil M; Tasan DA; Kaya A; Yavuz S; Ozden AI
    J Rheumatol; 2009 Mar; 36(3):491-500. PubMed ID: 19228660
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical evaluation of anti-mutated citrullinated vimentin by ELISA in rheumatoid arthritis.
    Soós L; Szekanecz Z; Szabó Z; Fekete A; Zeher M; Horváth IF; Dankó K; Kapitány A; Végvári A; Sipka S; Szegedi G; Lakos G
    J Rheumatol; 2007 Aug; 34(8):1658-63. PubMed ID: 17611988
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antibodies of IgG, IgA and IgM isotypes against cyclic citrullinated peptide precede the development of rheumatoid arthritis.
    Kokkonen H; Mullazehi M; Berglin E; Hallmans G; Wadell G; Rönnelid J; Rantapää-Dahlqvist S
    Arthritis Res Ther; 2011 Feb; 13(1):R13. PubMed ID: 21291540
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Increased prevalence of anti-third generation cyclic citrullinated peptide antibodies in patients with rheumatoid arthritis and CREST syndrome.
    Wu R; Shovman O; Zhang Y; Gilburd B; Zandman-Goddard G; Shoenfeld Y
    Clin Rev Allergy Immunol; 2007 Feb; 32(1):47-56. PubMed ID: 17426360
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Superior performance of the CCP3.1 test compared to CCP2 and MCV in the rheumatoid factor-negative RA population.
    Szekanecz Z; Szabó Z; Zeher M; Soós L; Dankó K; Horváth I; Lakos G
    Immunol Res; 2013 Jul; 56(2-3):439-43. PubMed ID: 23592053
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The presence of anti-citrullinated protein antibodies (ACPA) and rheumatoid factor on patients with rheumatoid arthritis (RA) does not interfere with the chance of clinical remission in a follow-up of 3 years.
    da Mota LM; Dos Santos Neto LL; de Carvalho JF; Pereira IA; Burlingame R; Ménard HA; Laurindo IM
    Rheumatol Int; 2012 Dec; 32(12):3807-12. PubMed ID: 22187055
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Relationship between rheumatoid factor isotypes and IgG anti-cyclic citrullinated peptide antibodies.
    Jaskowski TD; Hill HR; Russo KL; Lakos G; Szekanecz Z; Teodorescu M
    J Rheumatol; 2010 Aug; 37(8):1582-8. PubMed ID: 20516016
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-Citrullinated Protein Antibodies Are Associated With Neutrophil Extracellular Traps in the Sputum in Relatives of Rheumatoid Arthritis Patients.
    Demoruelle MK; Harrall KK; Ho L; Purmalek MM; Seto NL; Rothfuss HM; Weisman MH; Solomon JJ; Fischer A; Okamoto Y; Kelmenson LB; Parish MC; Feser M; Fleischer C; Anderson C; Mahler M; Norris JM; Kaplan MJ; Cherrington BD; Holers VM; Deane KD
    Arthritis Rheumatol; 2017 Jun; 69(6):1165-1175. PubMed ID: 28182854
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diagnostic performance of a new vimentin-derived ACPA (CCP high sensitive) in patients with rheumatoid arthritis.
    Bertin D; Dubucquoi S; Lakomy D; Deleplancque AS; Desplat-Jégo S
    Immunol Res; 2016 Apr; 64(2):455-60. PubMed ID: 26350265
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diagnostic value of anti-mutated citrullinated vimentin in comparison to anti-cyclic citrullinated peptide and anti-viral citrullinated peptide 2 antibodies in rheumatoid arthritis: an Italian multicentric study and review of the literature.
    Bartoloni E; Alunno A; Bistoni O; Bizzaro N; Migliorini P; Morozzi G; Doria A; Mathieu A; Lotzniker M; Allegri F; Riccieri V; Alpini C; Gabrielli A; Tampoia M; Gerli R;
    Autoimmun Rev; 2012 Sep; 11(11):815-20. PubMed ID: 22394488
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of the analytical and clinical performances of four anti-cyclic citrullinated peptide antibody assays for diagnosing rheumatoid arthritis.
    Cho J; Pyo JY; Fadriquela A; Uh Y; Lee JH
    Clin Rheumatol; 2021 Feb; 40(2):565-573. PubMed ID: 32964298
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-cyclic citrullinated peptide antibody isotypes in rheumatoid arthritis: association with disease duration, rheumatoid factor production and the presence of shared epitope.
    Lakos G; Soós L; Fekete A; Szabó Z; Zeher M; Horváth IF; Dankó K; Kapitány A; Gyetvai A; Szegedi G; Szekanecz Z
    Clin Exp Rheumatol; 2008; 26(2):253-60. PubMed ID: 18565246
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The diagnostic and prognostic value of IgG and IgA anti-citrullinated protein antibodies in patients with early rheumatoid arthritis.
    Sieghart D; Konrad C; Swiniarski S; Haslacher H; Aletaha D; Steiner G
    Front Immunol; 2022; 13():1096866. PubMed ID: 36685579
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.